Genespire

Biotechnology company focused on developing transformative gene therapies for patients affected by genetic diseases

Add To Watchlist
General Information
Company Name
Genespire
Founded Year
2020
Location (Offices)
Italy +1
Founders / Decision Makers
Julia Berretta - Chief Executive Officer Philippe Mauberna - Chief Financial Officer Alessio Cantore - Co-Founder & Scientific Sabah Sallah - Chief Medical Officer Julianne Smith - Chief Development Officer Luigi Naldini - Co-Founder, Scientific & Board Member
Number of Employees
15
Industries
Biotechnology, Life Sciences
Funding Stage
Series B
Social Media

Genespire - Company Profile

Genespire, a biotechnology company based in Milan, Italy, is dedicated to developing groundbreaking gene therapies for patients suffering from genetic diseases, with a focus on primary immunodeficiencies and inherited metabolic diseases. Established in March 2020 by gene therapy pioneer Prof. Luigi Naldini, Dr. Alessio Cantore, Fondazione Telethon, and Ospedale San Raffaele, Genespire is a spin-off of SR-Tiget, a world-leading cell and gene therapy research institute. The company recently secured a significant €46.60M Series B investment on 24 September 2024, with backing from prominent investors including Sofinnova Partners, Indaco Venture Partners, XGEN Venture, and CDP Venture Capital. Specializing in the biotechnology and life sciences industries, Genespire is poised to make a meaningful impact in the field of gene therapy.

Taxonomy: Gene therapy, Genetic diseases, Primary immunodeficiencies, Inherited metabolic diseases, Medical research, Cell therapy, Spin-off company, Research institute, Healthcare innovation, Durable gene therapies, Transformative treatments, Genetic medicine, Innovation in healthcare, Biomedical technology

Funding Rounds & Investors of Genespire (2)

View All
Funding Stage Amount No. Investors Investors Date
Series B €46.60M 4
Sofinnova Partners, investor in Genespire's Series B round Indaco Venture Partners, investor in Genespire's Series B round XGEN Venture, investor in Genespire's Series B round
CDP Venture Capital 		24 Sep 2024
Series A €16.00M 1
Sofinnova Partners, investor in Genespire's Series A round
29 Apr 2020

Latest News of Genespire

View All

No recent news or press coverage available for Genespire.

Similar Companies to Genespire

View All
Epigenic Therapeutics - Similar company to Genespire
Epigenic Therapeutics Pioneering Epigenetic Medicine
Gene Cradle - Similar company to Genespire
Gene Cradle Developing gene therapy drugs to treat rare genetic diseases and chronic conditions
Vivet Therapeutics - Similar company to Genespire
Vivet Therapeutics Vivet Therapeutics develops gene therapy treatments for inherited liver disorders using liver tropic virus.
Gene Vector - Similar company to Genespire
Gene Vector Pioneering the future of AAV gene therapy for ophthalmic, neuromuscular, genetic, and metabolic diseases.
Ocugen - Similar company to Genespire
Ocugen Approaching healthcare innovation with purpose and agility to deliver new breakthroughs for people facing disease.
Circle Decoration Circle Decoration

Want to dive deeper into Genespire? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now